Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow was wrong about that! Step away for two seconds and come back to nothing but ugliness LOL. Go USRM!
The channel is getting tighter and the bid is stacking up. Wait for it.........
Lol. Can’t stop it in my opinion!
A lot of buying around or VWAP (volume weighted average price) in the five minute chart. Indicative of institutional buying. It’s going to pop heart again today
Exactly what’s going on now. Consolidating for a continued run up.
crossed the 200 EMA on high volume. Finding support now at the 200. Bullish Confirmation. Take off some time after lunch. Next point of resistance in the six's. After six we close thee gap to eight. Coming soon!
daily chart looks so awesome!
USRM RECOGNIZED IN THE BATTLE AGAINST ALZHEIMERS..."Along with medication, there are natural supplements such as coconut oil, rosemary and certain vitamins that some medical experts believe can have positive effects on brain health. In addition, a group of doctors is looking at ways that stem cells can help. Kristin Comella, chief scientific officer at US Stem Cell, Inc. in Sunrise, said stem-cell therapy and regenerative medicine are novel treatments for diabetes and Alzheimer’s. Comella said stem cells have been shown to improve the function of the overworked pancreas in diabetes patients."
http://www.miamiherald.com/living/health-fitness/article186585028.html
I think we see fours by the end of the day! Nice flag in the 30 minute chart....
Nice, thank you for the article! Go $USRM!!!!
WOW!!!! GO $USRM!!!!!!!
US STEM CELL INCORPORATED (USRM) on Focus After Interesting Change
November 26, 2017 - By Adrian Mccoy
"Though penny shares are generally stated to be dicey, a trader can make massive amount of money in a short period of time, as against bigger, so-named ‘blue chip’ shares and mutual funds, which need a long-term plan."
Interesting analysis! didn't say much, but interesting.
http://finnewsdaily.com/us-stem-cell-incorporated-usrm-on-focus-after-interesting-change/
Haven’t been able to stop looking all weekend myself! Go $USRM
Tissue engineering, replacement organs and regenerative medicine are getting friendlier regulation
“Over the past few years scientists and physicians have developed tissue-engineered skin for transplant; bladders grown from a patient’s own cells; and tissues grown to repair ailing hearts or failing knees.
Development of tissue engineering and regenerative medicine are being boosted with the rules.”
https://www.nextbigfuture.com/2017/11/tissue-engineering-replacement-organs-and-regenerative-medicine-are-getting-friendlier-regulations.html
GOOD LUCK All. $USRM strong!
The brain shark link doesn't work on my desk top. Any suggestions?
http://us-stemcell.com/ceo-blog-november-2017-preparing-for-year-end-and-a-productive-2018/
CEO Blog: November 2017 Preparing for Year-End and a Productive 2018
Posted by U.S. Stem Cell, Inc
Dear Shareholders and Friends,
We are pleased to share with you highlights of our latest key milestones, as we prepare for year-end and the start of a productive 2018.
Our sixth-straight successful period of positive financial results continued in the 3rd quarter of 2017, including a revenue increase of 106 percent from the same quarter last year. Net increase in gross profit also rose 102 percent, while cash from operations for the nine months ended Sept. 30 increased 1004% from negative $113k in 2016 to more than $1m in 2017.
This quarter, we also announced the opening of a new clinic in West Palm Beach, Florida, bringing the number of clinics using our technology to 287. Our venture at Regenerative Wellness Clinic with Dr. Rosemary Daly, who will be utilizing U.S. Stem Cell’s proprietary technology for pain management and other therapeutics, is evidence of the continued expansion of our clinical distribution platform.
Opportunities in our five revenue centers — clinics, physician training and certification, stem cell processing kits, veterinarian training and kit sales and stem cell banking — continue to expand each year, as we make stem cell treatments available to more and more customers worldwide, with more than 700 USRM certified stem cell physicians globally.
On October 13th, our Chief Science Officer Dr. Kristin Comella presented for a second year at Bulletproof’s 5th Annual Biohacking Conference in Pasadena. Dr. Comella participated in an informational Stem Cell Panel, led by stem cell therapy expert Harry Adelson, ND. Bulletproof’s founder Dave Asprey, an avid, Stem-Cell advocate, invited Dr. Comella to present at the conference after he received a successful stem cell procedure at a U.S. Stem Cell clinic. Mr. Asprey received stem cell injections for brain health and sexual function.
U.S. Stem Cell Clinic also recently treated top fitness expert Ben Greenfield. You can watch his procedure here: https://www.facebook.com/BGFitness/videos/10156434268379179/
We’re also excited to announce the publication of a new study by Dr. Comella titled “Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases and Injuries Using the Stromal Vascular Fraction” in the prestigious Journal of Clinical Medical Research.
The study shows the efficacy and safety of autologous stem cell therapy in individuals with degenerative diseases and injuries, and is a treatment that’s helping to change people’s lives.
Dr. Comella will also be presenting this November at the 15th Annual Meeting of the International Federation for Adipose Therapeutics and Science (IFATS) from November 30 to December 3, 2017 in South Beach, Miami. She’ll discuss her paper, “Effects of the Intradiscal Implantation of Stromal Vascular Fraction Plus Platelet Rich Plasma in Patients With Degenerative Disc Disease.” Patients demonstrated a statistically significant improvement in range of motion, pain reduction and quality of life, with no severe adverse events linked to the therapy. A link to the paper can be found here: http://bit.ly/2yDd33l
Finally, as you may know, we have issued a response to the FDA’s warning letter to US Stem Cell Clinic. We have engaged a large Washington, D.C. law firm who specializes in FDA case law to assist in our communications. We are having open communications with the agency and look forward to their responses.
We are committed to preserving the rights of patients to harness their bodies’ own healing potential. Our dedication to this emerging science is unwavering and we will continue to expand efforts to help patients maximize their health with this amazing technology.
We thank you for your interest and continued support.
Warmest regards,
Mike Tomas,
President and CEO
CHECK THIS OUT:
"The draft guidance states that it is possible that the preliminary evidence needed for RMAT designation could come from clinical trials with “appropriately chosen” historical controls, well-designed retrospective studies, or even “clinical case series that provide data systematically collected by treating physicians.” If an RMAT-designated product also receives an accelerated approval based on a surrogate endpoint, FDA could accept “patient registries, or other sources of real world evidence, such as electronic health records” to satisfy post-approval requirements. "
"The interpretation in the draft guidance for gene therapies is significant because there has been uncertainty about the scope of RMAT eligibility. One of the criteria for RMAT eligibility is that the drug must be a “regenerative medicine therapy,” which “includes cell therapy, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products.” 21 USC 356(g)(8). Because the term “gene therapy” was not expressly included in the regenerative medicine therapy definition, some feared that gene therapies may have been excluded."
https://www.lexology.com/library/detail.aspx?g=5ac025f7-b03e-41d3-b0a8-30d39fb0aeeb
Can you say....KABOOM!
Nice 100k ask slap.
DON'T FORGET FRTT.
"In response to Bellina’s testimony to Congress and years of public advocacy, Wisconsin Republican Sen. Ron Johnson introduced a Federal Right to Try bill with Democratic Sens. Joe Donnelly, D-Ind.; Joe Manchin, D-W.V.; Angus King, I-Maine; and 40 Republicans as co-sponsors. President Trump supported it too. The bill passed the Senate on August 1, 2017 and was referred to the House of Representatives for final action."
https://spectator.org/abigails-16-year-senate-victory-over-fda-bureaucrats/
What do we have, 9 days until options expire?? Form fours file on sept 1.
I think there’s a surprise coming soon as well. Additionally, the FDA will have conflict of interest with the RTT states. Thirty Seven now. We will have to see how this plays out, but I earnings, revenue, and sales don’t lie.
GO $USRM!!!
Moderator. Sticky this please
The FDA guidelines open the door for good news......
Gotta learn to see the silver lining........
What are you talking about rink. My account is green! Three years to comply dude. What’s everyone worried about, that’s great news......
FDA ROLLED OUT NEW GUIDELINES YESTERDAY. 3 YEARS TO COMPLY. http://www.latimes.com/business/hiltzik/la-fi-hiltzik-fda-stem-cell-20171117-story.html
Bad day for bears. Good day for WPRT!
Nice, I've been buying on the bid lately because I threw so much money at the ask only to see that they were going to do whatever they wanted with the PPS regardless of my ask slapping.
Yep, level 2 stacking up on the bid.
Got it. Now I understand why everyone always says to slap the ask.
up from here. Price is way over extended to the down side on any chart you look at.
Damn, they are doing a great job. Accumulation still at 720 million. I'm not scared.
https://presstelegraph.com/us-stem-cell-incorporated-usrm-in-motion-strong-momentum-for-holders/
"US STEM CELL INCORPORATED’s shares has traded at $3134.83 month over month. The short interest of stock currently stands at 287,900 against short interest of 8,900 last month. Investors have 0.1 days to close the position."
correct me if I'm wrong but this article is saying that shorts have till today to close their positions, does it not?
http://www.nasdaq.com/article/why-westport-fuel-systems-wprt-might-surprise-this-earnings-season-cm876322
"That is because Westport Fuel Systems is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for WPRT in this report."
"Given that WPRT has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings."
Nice! That's very nice! Congratulations, and may the best call, or short, win. Good luck to you Jack.
For instance, I closed my 3000 shares out at roughly 2.87 after getting in at 1.64. The stock surprised me and took another leg up, but it was right to collect profits when I did.
I now own 60 calls on WPRT with a max risk of $900 in anticipation of earnings. If I'm wrong I lose a few hundred rather than all my gains from the previous run.
Less than 15% drop after a 100% run MEANS NOTHING!!!!
100% increase in PPS from last earnings report, a less than 15% correction right before earnings with a run like that means nothing. Smart money will protect their profits and be ready to reinvest once a good earnings report is issued.
Go $WPRT